Advancing the Science of Radiopharmaceuticals Conjugations Radiolabeling Research & 

Advancing the
Science of Radiopharmaceuticals
Conjugations Radiolabeling Research & 


Years Combined

Who We Are

Your Partner -
Proposal to Product

IsoTherapeutics offers technologies for developing novel therapeutic and diagnostic agents for severe diseases.

IsoTherapeutics scientists have received over 100 patents for developing chemistry and radiopharmaceutical formulations.

IsoTherapeutics has been acquired by Telix Pharmaceuticals.

Our Services

IsoTherapeutics offers A host of services to the pharmaceutical and life-science industries.

The range of services include helping customers/partners with early stage research from proof of concept for a new chemistry or drug molecule through making of the drug in a cGMP facility for preclinical studies. These services include:

State of the Art


IsoTherapeutics is located 45 miles south of Houston at 1004 South Velasco Street in Angleton, Texas. The facility consists of three buildings equipped with offices, R&D laboratories, cGMP production area, documentation room, shipping and receiving, controlled storage areas and an animal research laboratory.

Cutting Edge


IsoTherapeutics has a variety of radioanalytical counting equipment including alpha, beta, and gamma counters. Most of the work with radiopharmaceuticals is done using NaI well crystals which we have coupled to multichannel analyzers and sample changers. We also have several Ge crystals for high resolution gamma spectroscopy plus liquid scintillation capabilities to work with beta-emitting radionuclides.

We Work With These


Got a Project? Let's Schedule An Appointment

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 9 April 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the completion of the acquisition of IsoTherapeutics Group, LLC (IsoTherapeutics).

IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix. The acquisition further enhances Telix’s in-house development capabilities and expands Telix’s United States (U.S.) manufacturing footprint with particular focus on bioconjugation and isotope processing.

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “The acquisition of IsoTherapeutics Group is a significant milestone in Telix’s continued focus on vertical integration of development, supply and manufacturing and is highly complementary to Optimal Tracers (Sacramento, California), ARTMS (Vancouver) and our extensive commercial manufacturing infrastructure in Belgium. In the IsoTherapeutics team, we have partnered with some of the leading experts in radiochemistry and I am excited at what we can achieve together going forward.”